Background: Neuraminidase (NA) inhibitors are the recommended antiviral medications for influenza treatment. However, their therapeutic efficacy can be compromised by NA changes that emerge naturally and/or following antiviral treatment. Knowledge of which molecular changes confer drug resistance of influenza A(H7N9) viruses (group 2NA) remains sparse. Methods: Fourteen amino acid substitutions were introduced into the NA of A/Shanghai/2/2013(H7N9). Recombinant N9 (recN9) proteins were expressed in a baculovirus system in insect cells and tested using the Centers for Disease Control and Prevention standardized NA inhibition (NI) assay with oseltamivir, zanamivir, peramivir, and laninamivir. The wild-type N9 crystal structure was determined in complex with oseltamivir, zanamivir, or sialic acid, and structural analysis was performed. Results: All substitutions conferred either reduced or highly reduced inhibition by at least 1 NA inhibitor; half of them caused reduced inhibition or highly reduced inhibition by all NA inhibitors. R292K conferred the highest increase in oseltamivir half-maximal inhibitory concentration (IC50), and E119D conferred the highest zanamivir IC50. Unlike N2 (another group 2NA), H274Y conferred highly reduced inhibition by oseltamivir. Additionally, R152K, a naturally occurring variation at the NA catalytic residue of A(H7N9) viruses, conferred reduced inhibition by laninamivir. Conclusions: The recNA method is a valuable tool for assessing the effect of NA changes on drug susceptibility of emerging influenza viruses. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Neuraminidase (NA) inhibitors are the recommended antiviral medications for influenza treatment. However, their therapeutic efficacy can be compromised by NA changes that emerge naturally and/or following antiviral treatment. Knowledge of which molecular changes confer drug resistance of influenza A(H7N9) viruses (group 2NA) remains sparse. Methods: Fourteen amino acid substitutions were introduced into the NA of A/Shanghai/2/2013(H7N9). Recombinant N9 (recN9) proteins were expressed in a baculovirus system in insect cells and tested using the Centers for Disease Control and Prevention standardized NA inhibition (NI) assay with oseltamivir, zanamivir, peramivir, and laninamivir. The wild-type N9 crystal structure was determined in complex with oseltamivir, zanamivir, or sialic acid, and structural analysis was performed. Results: All substitutions conferred either reduced or highly reduced inhibition by at least 1 NA inhibitor; half of them caused reduced inhibition or highly reduced inhibition by all NA inhibitors. R292K conferred the highest increase in oseltamivir half-maximal inhibitory concentration (IC50), and E119D conferred the highest zanamivir IC50. Unlike N2 (another group 2NA), H274Y conferred highly reduced inhibition by oseltamivir. Additionally, R152K, a naturally occurring variation at the NA catalytic residue of A(H7N9) viruses, conferred reduced inhibition by laninamivir. Conclusions: The recNA method is a valuable tool for assessing the effect of NA changes on drug susceptibility of emerging influenza viruses. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
A(H7N9); Neuraminidase; bird flu; drug resistance; recombinant protein
Authors: Victor A Streltsov; Peter M Schmidt; Jennifer L McKimm-Breschkin Journal: Acta Crystallogr F Struct Biol Commun Date: 2019-01-23 Impact factor: 1.056
Authors: Lei Yang; Jianfeng Xie; Ye Zhang; Wenfei Zhu; Xiyan Li; Hejiang Wei; Zi Li; Lin Zhao; Hong Bo; Jia Liu; Jie Dong; Tao Chen; Yuelong Shu; Yuwei Weng; Dayan Wang Journal: Influenza Other Respir Viruses Date: 2019-06-11 Impact factor: 4.380
Authors: Erin N Hodges; Vasiliy P Mishin; Juan De la Cruz; Zhu Guo; Ha T Nguyen; Eric Fallows; James Stevens; David E Wentworth; Charles Todd Davis; Larisa V Gubareva Journal: Influenza Other Respir Viruses Date: 2019-06-11 Impact factor: 4.380
Authors: Wen-Hung Wang; Esmeralda Merari Erazo; Max R Chang Ishcol; Chih-Yen Lin; Wanchai Assavalapsakul; Arunee Thitithanyanont; Sheng-Fan Wang Journal: J Int Med Res Date: 2019-05-08 Impact factor: 1.671
Authors: Annika Suttie; Yi-Mo Deng; Andrew R Greenhill; Philippe Dussart; Paul F Horwood; Erik A Karlsson Journal: Virus Genes Date: 2019-08-19 Impact factor: 2.332